HomeCompareBMY vs GD

BMY vs GD: Dividend Comparison 2026

BMY yields 4.17% · GD yields 1.76%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 BMY wins by $76.5K in total portfolio value
10 years
BMY
BMY
● Live price
4.17%
Share price
$59.73
Annual div
$2.49
5Y div CAGR
37%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$120.5K
Annual income
$39,823.66
Full BMY calculator →
GD
GD
● Live price
1.76%
Share price
$340.79
Annual div
$6.00
5Y div CAGR
36.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$44.0K
Annual income
$7,409.33
Full GD calculator →

Portfolio growth — BMY vs GD

📍 BMY pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodBMYGD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, BMY + GD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
BMY pays
GD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BMY
Annual income on $10K today (after 15% tax)
$354.34/yr
After 10yr DRIP, annual income (after tax)
$33,850.11/yr
GD
Annual income on $10K today (after 15% tax)
$149.65/yr
After 10yr DRIP, annual income (after tax)
$6,297.93/yr
At 15% tax rate, BMY beats the other by $27,552.18/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BMY + GD for your $10,000?

BMY: 50%GD: 50%
100% GD50/50100% BMY
Portfolio after 10yr
$82.3K
Annual income
$23,616.49/yr
Blended yield
28.71%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on BMY right now

BMY
Analyst Ratings
19
Buy
20
Hold
2
Sell
Consensus: Hold
Price Target
$62.73
+5.0% upside vs current
Range: $40.00 — $75.00
Altman Z
2.3
Piotroski
8/9
GD
Analyst Ratings
17
Buy
16
Hold
1
Sell
Consensus: Buy
Price Target
$404.22
+18.6% upside vs current
Range: $385.00 — $444.00
Altman Z
4.2
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BMY buys
0
GD buys
0
No recent congressional trades found for BMY or GD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricBMYGD
Forward yield4.17%1.76%
Annual dividend / share$2.49$6.00
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR37%36.6%
Portfolio after 10y$120.5K$44.0K
Annual income after 10y$39,823.66$7,409.33
Total dividends collected$91.0K$21.2K
Payment frequencyquarterlyquarterly
SectorHealthcareIndustrials
Analyst consensusHoldBuy
Analyst price target$62.73$404.22

Year-by-year: BMY vs GD ($10,000, DRIP)

YearBMY PortfolioBMY Income/yrGD PortfolioGD Income/yrGap
1← crossover$11,271$571.12$10,941$240.50+$330.00BMY
2$12,884$824.20$12,042$335.91+$842.00BMY
3$14,993$1,206.32$13,357$472.02+$1.6KBMY
4$17,839$1,797.27$14,961$668.39+$2.9KBMY
5$21,826$2,738.11$16,964$955.72+$4.9KBMY
6$27,643$4,289.31$19,534$1,383.46+$8.1KBMY
7$36,534$6,955.64$22,936$2,033.85+$13.6KBMY
8$50,861$11,770.13$27,590$3,048.57+$23.3KBMY
9$75,402$20,980.23$34,203$4,681.66+$41.2KBMY
10$120,504$39,823.66$44,006$7,409.33+$76.5KBMY

BMY vs GD: Complete Analysis 2026

BMYHealthcare

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.

Full BMY Calculator →

GDIndustrials

General Dynamics Corporation operates as an aerospace and defense company worldwide. It operates through four segments: Aerospace, Marine Systems, Combat Systems, and Technologies. The Aerospace segment designs, manufactures, and sells business jets; and offers aircraft maintenance and repair, management, charter, aircraft-on-ground support and completion, staffing, and fixed-base operator services. The Marine Systems segment designs and builds nuclear-powered submarines, surface combatants, and auxiliary ships for the United States Navy and Jones Act ships for commercial customers, as well as builds crude oil and product tankers, and container and cargo ships. This segment also provides navy ships maintenance and modernization services; lifecycle support and repair services for navy surface ships; and program management, planning, engineering, and design support services for submarines and surface ships. The Combat Systems segment manufactures land combat solutions, such as wheeled and tracked combat vehicles, Stryker wheeled combat vehicles, piranha vehicles, weapons systems, munitions, mobile bridge systems with payloads, tactical vehicles, main battle tanks, armored vehicles, and armaments. This segment also offers modernization programs, engineering, support, and sustainment services. The Technologies segment provides information technology solutions and mission support services; mobile communication, computers, and command-and-control mission systems; and intelligence, surveillance, and reconnaissance solutions to military, intelligence, and federal civilian customers. This segment also offers cloud computing, artificial intelligence; machine learning; big data analytics; development, security, and operations; software-defined networks; everything-as-a-service; defense enterprise office system solutions; and unmanned undersea vehicle manufacturing and assembly services. General Dynamics Corporation was founded in 1899 and is headquartered in Reston, Virginia.

Full GD Calculator →
📬

Get this BMY vs GD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BMY vs SCHDBMY vs JEPIBMY vs OBMY vs KOBMY vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.